Related Experiment Videos
Lack of relationship between Clostridium difficile toxin and inflammatory bowel disease in children
Insights
Routine screening for Clostridium difficile toxin is not recommended for children with inflammatory bowel disease (IBD). The study found a low incidence of toxin positivity in pediatric IBD patients, suggesting it is generally unwarranted.
Area of Science:
- Pediatric Gastroenterology
- Infectious Diseases
- Microbiology
Background:
- The role of Clostridium difficile toxin in pediatric inflammatory bowel disease (IBD) remains controversial.
- Previous reports on C. difficile toxin incidence in IBD patients have yielded conflicting results.
Purpose of the Study:
- To prospectively evaluate the incidence of Clostridium difficile toxin in children diagnosed with IBD.
- To assess the correlation between C. difficile toxin presence and IBD severity, recent antibiotic use, and hospitalization.
Main Methods:
- Prospective study over 1 year involving 44 children with IBD.
- Collection and analysis of 128 stool specimens for C. difficile toxin.
- Clinical data including disease severity, hospitalization, and antibiotic exposure were recorded.
Main Results:
- Only 3 out of 128 stool specimens (2.3%) tested positive for C. difficile toxin.
- Toxin-positive cases occurred in three different children with moderate Crohn's disease, without recent hospitalization or antibiotic exposure.
- Stools became toxin-negative within 3 weeks without clinical changes; no severe cases or those with recent antibiotic/sulfasalazine exposure were toxin-positive.
Conclusions:
- Routine screening for Clostridium difficile toxin in pediatric inflammatory bowel disease patients is not clinically warranted.
- The low incidence suggests C. difficile toxin is unlikely to be a significant factor in most pediatric IBD cases.
- Further investigation may be needed for specific subgroups, but general screening appears unnecessary.
Abstract:
Conflicting reports have appeared concerning the role of Clostridium difficile toxin in chronic inflammatory bowel disease. Therefore, we prospectively evaluated the incidence of C. difficile toxin in 44 children with inflammatory bowel disease of variable clinical severity over a 1-year period. Only 3/128 stool specimens provided by these patients were found to be toxin-positive. These three stool specimens were from three different patients with Crohn's disease of moderate severity who had no recent hospitalization or antibiotic exposure. None received vancomycin therapy and their stools became toxin-negative over 3 weeks with no apparent change in the patients' clinical condition. No patient with severe disease or recent exposure to antibiotics or sulfasalazine was found to have toxin-positive stools. Routine screening for C. difficile toxin in children with inflammatory bowel disease appears unwarranted.